Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells

Xiaodong Wen, Celia Chao, Kirk Ives, Mark Hellmich

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Cyclooxygenase-2 (COX-2) and the bombesin (BBS)-like peptide, gastrin-releasing peptide (GRP), have been implicated in the progression of hormone-refractory prostate cancer; however, a mechanistic link between the bioactive peptide and COX-2 expression in prostate cells has not been made.Results: We report that BBS stimulates COX-2 mRNA and protein expression, and the release of prostaglandin E2 from the GRP receptor (GRPR)-positive, androgen-insensitive prostate cancer cell line, PC-3. BBS-stimulated COX-2 expression is mediated, in part, by p38MAPK and PI3 kinase (PI3K)/Akt pathways, and blocked by a GRPR antagonist. The PI3K/Akt pathway couples GRPR to the transcription factor, activator protein-1 (AP-1), and enhanced COX-2 promoter activity. Although BBS stimulates nuclear factor-kappaB (NF-κB) in PC-3, NF-κB does not regulate GRPR-mediated COX-2 expression. The p38MAPK pathway increases BBS-stimulated COX-2 expression by slowing the degradation of COX-2 mRNA. Expression of recombinant GRPR in the androgen-sensitive cell line LNCaP is sufficient to confer BBS-stimulated COX-2 expression via the p38MAPK and PI3K/Akt pathways.Conclusions: Our study establishes a mechanistic link between GRPR activation and enhanced COX-2 expression in prostate cancer cell lines, and suggests that inhibiting GRPR may, in the future, provide an effective therapeutic alternative to non-steroidal anti-inflammatory drugs for inhibiting COX-2 in patients with recurrent prostate cancer.

Original languageEnglish (US)
Article number29
JournalBMC Molecular Biology
Volume12
DOIs
StatePublished - Jul 11 2011

Fingerprint

Bombesin
Cyclooxygenase 2
Prostatic Neoplasms
Phosphatidylinositol 3-Kinases
Cell Line
Bombesin Receptors
Gastrin-Releasing Peptide
Messenger RNA
Peptides
Transcription Factor AP-1
Androgen Receptors
Dinoprostone
Androgens
Prostate
Anti-Inflammatory Agents
Transcription Factors
Hormones

Keywords

  • Gastrin-releasing peptide receptor
  • Hormone-refractory
  • Neuroendocrine differentiation
  • Prostate cancer
  • Signal transduction

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells. / Wen, Xiaodong; Chao, Celia; Ives, Kirk; Hellmich, Mark.

In: BMC Molecular Biology, Vol. 12, 29, 11.07.2011.

Research output: Contribution to journalArticle

@article{c800ac24253d452b8379a9bc20cd23cb,
title = "Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells",
abstract = "Background: Cyclooxygenase-2 (COX-2) and the bombesin (BBS)-like peptide, gastrin-releasing peptide (GRP), have been implicated in the progression of hormone-refractory prostate cancer; however, a mechanistic link between the bioactive peptide and COX-2 expression in prostate cells has not been made.Results: We report that BBS stimulates COX-2 mRNA and protein expression, and the release of prostaglandin E2 from the GRP receptor (GRPR)-positive, androgen-insensitive prostate cancer cell line, PC-3. BBS-stimulated COX-2 expression is mediated, in part, by p38MAPK and PI3 kinase (PI3K)/Akt pathways, and blocked by a GRPR antagonist. The PI3K/Akt pathway couples GRPR to the transcription factor, activator protein-1 (AP-1), and enhanced COX-2 promoter activity. Although BBS stimulates nuclear factor-kappaB (NF-κB) in PC-3, NF-κB does not regulate GRPR-mediated COX-2 expression. The p38MAPK pathway increases BBS-stimulated COX-2 expression by slowing the degradation of COX-2 mRNA. Expression of recombinant GRPR in the androgen-sensitive cell line LNCaP is sufficient to confer BBS-stimulated COX-2 expression via the p38MAPK and PI3K/Akt pathways.Conclusions: Our study establishes a mechanistic link between GRPR activation and enhanced COX-2 expression in prostate cancer cell lines, and suggests that inhibiting GRPR may, in the future, provide an effective therapeutic alternative to non-steroidal anti-inflammatory drugs for inhibiting COX-2 in patients with recurrent prostate cancer.",
keywords = "Gastrin-releasing peptide receptor, Hormone-refractory, Neuroendocrine differentiation, Prostate cancer, Signal transduction",
author = "Xiaodong Wen and Celia Chao and Kirk Ives and Mark Hellmich",
year = "2011",
month = "7",
day = "11",
doi = "10.1186/1471-2199-12-29",
language = "English (US)",
volume = "12",
journal = "BMC Molecular Biology",
issn = "1471-2199",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells

AU - Wen, Xiaodong

AU - Chao, Celia

AU - Ives, Kirk

AU - Hellmich, Mark

PY - 2011/7/11

Y1 - 2011/7/11

N2 - Background: Cyclooxygenase-2 (COX-2) and the bombesin (BBS)-like peptide, gastrin-releasing peptide (GRP), have been implicated in the progression of hormone-refractory prostate cancer; however, a mechanistic link between the bioactive peptide and COX-2 expression in prostate cells has not been made.Results: We report that BBS stimulates COX-2 mRNA and protein expression, and the release of prostaglandin E2 from the GRP receptor (GRPR)-positive, androgen-insensitive prostate cancer cell line, PC-3. BBS-stimulated COX-2 expression is mediated, in part, by p38MAPK and PI3 kinase (PI3K)/Akt pathways, and blocked by a GRPR antagonist. The PI3K/Akt pathway couples GRPR to the transcription factor, activator protein-1 (AP-1), and enhanced COX-2 promoter activity. Although BBS stimulates nuclear factor-kappaB (NF-κB) in PC-3, NF-κB does not regulate GRPR-mediated COX-2 expression. The p38MAPK pathway increases BBS-stimulated COX-2 expression by slowing the degradation of COX-2 mRNA. Expression of recombinant GRPR in the androgen-sensitive cell line LNCaP is sufficient to confer BBS-stimulated COX-2 expression via the p38MAPK and PI3K/Akt pathways.Conclusions: Our study establishes a mechanistic link between GRPR activation and enhanced COX-2 expression in prostate cancer cell lines, and suggests that inhibiting GRPR may, in the future, provide an effective therapeutic alternative to non-steroidal anti-inflammatory drugs for inhibiting COX-2 in patients with recurrent prostate cancer.

AB - Background: Cyclooxygenase-2 (COX-2) and the bombesin (BBS)-like peptide, gastrin-releasing peptide (GRP), have been implicated in the progression of hormone-refractory prostate cancer; however, a mechanistic link between the bioactive peptide and COX-2 expression in prostate cells has not been made.Results: We report that BBS stimulates COX-2 mRNA and protein expression, and the release of prostaglandin E2 from the GRP receptor (GRPR)-positive, androgen-insensitive prostate cancer cell line, PC-3. BBS-stimulated COX-2 expression is mediated, in part, by p38MAPK and PI3 kinase (PI3K)/Akt pathways, and blocked by a GRPR antagonist. The PI3K/Akt pathway couples GRPR to the transcription factor, activator protein-1 (AP-1), and enhanced COX-2 promoter activity. Although BBS stimulates nuclear factor-kappaB (NF-κB) in PC-3, NF-κB does not regulate GRPR-mediated COX-2 expression. The p38MAPK pathway increases BBS-stimulated COX-2 expression by slowing the degradation of COX-2 mRNA. Expression of recombinant GRPR in the androgen-sensitive cell line LNCaP is sufficient to confer BBS-stimulated COX-2 expression via the p38MAPK and PI3K/Akt pathways.Conclusions: Our study establishes a mechanistic link between GRPR activation and enhanced COX-2 expression in prostate cancer cell lines, and suggests that inhibiting GRPR may, in the future, provide an effective therapeutic alternative to non-steroidal anti-inflammatory drugs for inhibiting COX-2 in patients with recurrent prostate cancer.

KW - Gastrin-releasing peptide receptor

KW - Hormone-refractory

KW - Neuroendocrine differentiation

KW - Prostate cancer

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=79960063902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960063902&partnerID=8YFLogxK

U2 - 10.1186/1471-2199-12-29

DO - 10.1186/1471-2199-12-29

M3 - Article

VL - 12

JO - BMC Molecular Biology

JF - BMC Molecular Biology

SN - 1471-2199

M1 - 29

ER -